These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19649209)

  • 1. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
    Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM
    Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
    Wallace A; LaRosa DF; Kapoor V; Sun J; Cheng G; Jassar A; Blouin A; Ching LM; Albelda SM
    Cancer Res; 2007 Jul; 67(14):7011-9. PubMed ID: 17638914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors.
    Wang LC; Woon ST; Baguley BC; Ching LM
    Oncol Res; 2006; 16(1):1-14. PubMed ID: 16783963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
    Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
    Wang LC; Ching LM; Paxton JW; Kestell P; Sutherland R; Zhuang L; Baguley BC
    Invest New Drugs; 2009 Jun; 27(3):280-4. PubMed ID: 18696010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
    Wang LC; Reddy CB; Baguley BC; Kestell P; Sutherland R; Ching LM
    Biochem Pharmacol; 2004 Mar; 67(5):937-45. PubMed ID: 15104247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
    Sun J; Wang LC; Fridlender ZG; Kapoor V; Cheng G; Ching LM; Albelda SM
    Biochem Pharmacol; 2011 Nov; 82(9):1175-85. PubMed ID: 21819972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
    Smolarczyk R; Cichoń T; Pilny E; Jarosz-Biej M; Poczkaj A; Kułach N; Szala S
    Sci Rep; 2018 May; 8(1):7355. PubMed ID: 29743548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
    Philpott M; Ching LM; Baguley BC
    Eur J Cancer; 2001 Oct; 37(15):1930-7. PubMed ID: 11576850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
    Zhao L; Ching LM; Kestell P; Kelland LR; Baguley BC
    Int J Cancer; 2005 Aug; 116(2):322-6. PubMed ID: 15800918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.